

Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects

Federico L Dente, Lorenza Bancalari, Elena Bacci, Maria L Bartoli, Stefano Carnevali, Silvana Cianchetti, Antonella Di Franco, Daniele Giannini, Barbara Vagaggini, Renato Testi, Pier L Paggiaro

Abstract

Background—The long acting β_2 agonist salmeterol is very effective in preventing asthmatic responses to specific stimuli, and this effect could theoretically be due to some anti-inflammatory property in addition to bronchodilator property.

Methods—The protective effect of a single dose of salmeterol (50 μg) on allergen induced early and late responses and on the associated airway inflammation was investigated in a double blind, placebo controlled, crossover study in 11 atopic asthmatic subjects. Eosinophil percentages and concentrations of eosinophil cationic protein (ECP) in peripheral blood and in hypertonic saline induced sputum were measured 24 hours after allergen inhalation.

Results—Salmeterol effectively inhibited both early and late asthmatic responses in comparison with placebo. Salmeterol also inhibited the increase in the percentage of eosinophils in the sputum 24 hours after allergen inhalation (median (range) baseline 6% (1–36), after placebo 31% (5–75), after salmeterol 12% (1–63)). However, the increase in both sputum and serum ECP concentrations 24 hours after allergen challenge was not affected by pretreatment with salmeterol.

Conclusions—A single dose of salmeterol inhibits the allergen induced airway responses and the increase in sputum eosinophils after allergen challenge.

(Thorax 1999;54:622–624)

Keywords: β agonist; salmeterol; asthma; allergen bronchial challenge; eosinophils

It is known that long acting β_2 agonists are effective in controlling asthma symptoms and improving lung function.¹ Additionally, long acting β_2 agonists have shown some in vitro anti-inflammatory properties but it is controversial whether they have similar effects in vivo. There is indirect evidence that long acting β_2 agonists inhibit the late asthmatic reaction (LAR) following inhaled allergen challenge and

the associated increase in bronchial hyperresponsiveness.² Moreover, pretreatment with salmeterol before allergen challenge induced a significant decrease in the concentration of eosinophil cationic protein (ECP) but not of the differential cell count in bronchoalveolar lavage (BAL) fluid obtained 24 hours after allergen inhalation.³ By analysis of sputum induced by inhalation of hypertonic saline, some investigators reported no effect of a single dose of salmeterol on the increase in eosinophil percentages induced by allergen inhalation in sensitised asthmatics.⁴ In this study we examined whether a single dose of salmeterol is able to reduce the increase in the number of sputum eosinophils induced by allergen challenge in sensitised asthmatic subjects.

Methods

Eleven mild asthmatic subjects (eight men) of mean age 20 years (range 16–27) with positive skin prick tests to *Dermatophagoides pteronyssinus* were selected. All subjects showed normal baseline forced expiratory volume in one second (FEV₁) (mean 93% predicted (range 83–121)), non-specific bronchial hyperresponsiveness to methacholine (geometric mean 0.134 mg (range 0.037–0.59)), and an early asthmatic response (EAR) followed by an LAR to specific bronchial challenge with *D pteronyssinus* in a screening test. All patients were treated with occasional inhaled salbutamol on demand only during the preceding month and had no respiratory infections. Each subject performed two allergen inhalation tests at four week intervals 15 minutes after two puffs of salmeterol (50 μg) or placebo, administered in double blind, randomised, crossover design. At seven hours a methacholine challenge test was performed (results not presented). At 24 hours after allergen inhalation, hypertonic saline induced sputum and blood samples were collected for measurement of total and differential cells and ECP concentration. In each allergen challenge the same total dose of allergen administered in the screening test was inhaled step by step.

Specific bronchial provocative tests were performed with allergens standardised in bio-

Cardio-Thoracic Department, Pneumology Section, University of Pisa, Pisa, Italy

F L Dente
L Bancalari
E Bacci
M L Bartoli
S Carnevali
S Cianchetti
A Di Franco
D Giannini
B Vagaggini
P L Paggiaro

GlaxoWellcome, Verona, Italy
R Testi

Correspondence to:
Dr F L Dente, Ospedale di Cisanello, Dipartimento di Cardiologia Angiologia e Pneumologia, U.O. di Fisiopatologia Respiratoria, via Paradisa 2, 56100 Pisa, Italy.

Received 24 June 1998
Returned to author
28 August 1998
Revised manuscript received
18 March 1999
Accepted for publication
22 March 1999

Table 1 Inflammatory indices of eosinophil activation in sputum and blood

Subject no.	Sputum eosinophil number (% inflammatory cells)			Sputum ECP ($\mu\text{g/ml}$)			Blood eosinophil number (% inflammatory cells)			Serum ECP ($\mu\text{g/ml}$)		
	Baseline	24 h after sBPT pretreated with placebo	24 h after sBPT pretreated with salmeterol	Baseline	24 h after sBPT pretreated with placebo	24 h after sBPT pretreated with salmeterol	Baseline	24 h after sBPT pretreated with placebo	24 h after sBPT pretreated with salmeterol	Baseline	24 h after sBPT pretreated with placebo	24 h after sBPT pretreated with salmeterol
	1	4.5	38.0	8.0	38	287	69	6.1	13.7	10.9	4.1	7.8
2	20.0	59.5	27.5	81	1402	188	—	—	—	5.5	14.1	3.8
3	2.3	30.6	5.3	30	584	475	5.7	7.3	11.3	3.5	8.8	11.7
4	35.6	75.0	54.8	315	5473	1784	13.3	1.2	0.4	9.8	4.6	3.1
5	2.8	6.0	1.6	51	102	70	3.4	6.3	4.9	6.9	16.6	7.6
6	11.0	5.4	8.7	91	190	112	9.0	6.7	8.5	6.2	5.4	10.0
7	4.6	23.7	30.1	462	1292	2398	6.8	6.8	8.2	4.0	3.8	3.2
8	17.5	49.7	63.3	1398	3060	8817	13.7	16.1	18.9	36.5	46.4	43.4
9	5.8	13.7	1.1	64	144	1087	2.3	7.0	3.9	4.0	13.1	9.1
10	17.8	49.9	12.3	104	309	67	10.3	12.9	—	6.6	13.0	53.5
11	1.0	27.3	19.1	87	—	—	8.2	8.8	5.9	2.8	3.5	20.5
Median	5.8	30.6*	12.3§				8.2	7.0	8.2			
Geometric mean				116	581*	410*				6.0	9.2*	9.4*

* $p < 0.05$ versus baseline; § $p < 0.05$ versus placebo.

sBPT = specific bronchial provocative test; ECP = eosinophil cationic protein

logical units (BU) (NeoAbellò, Milano, Italy). Allergen extract solution was delivered by a DeVilbiss 646 jet nebuliser (DeVilbiss Health Care, Somerset, Pennsylvania, USA) using a procedure previously described.⁵ EAR and LAR were measured as percentage falls in FEV_1 with respect to baseline 10–60 minutes and 3–7 hours, respectively, after allergen inhalation. EAR and LAR were considered significant when the percentage falls in FEV_1 were greater than 20%.

Sputum was induced and processed according to the method of Pin *et al.*,⁶ slightly modified.⁷ ECP concentrations were measured in blood and sputum supernatant using a specific radioimmunological method (ECP RIA, Pharmacia, Uppsala, Sweden).⁸

ANOVA and paired *t* tests were used to compare FEV_1 , $\text{PD}_{20}\text{FEV}_1$, and serum or sputum ECP concentrations, while the Mann-Whitney test was used to compare sputum and blood differential cell percentages. A level of probability lower than 5% was considered significant.⁹




Figure 1 Mean (SE) values of FEV_1 before and up to seven hours after allergen challenge in subjects pretreated with placebo (open circles) or salmeterol (closed circles). ** $p < 0.01$ between placebo and salmeterol.

Results

Pretreatment with salmeterol produced a significant increase in FEV_1 compared with placebo (mean (SD) ΔFEV_1 10 (5)% after salmeterol, 4 (5)% after placebo, $p < 0.05$) and an inhibition of both EAR (median (range) ΔFEV_1 -2% (-28 to +2) after salmeterol, -41% (-57 to -27) after placebo, $p < 0.01$) and LAR (median (range) ΔFEV_1 -5% (-37 to +6) after salmeterol, -45% (-65 to -20) after placebo, $p < 0.01$; fig 1). After pretreatment with salmeterol EAR persisted in one subject and LAR in three.

Sputum was successfully obtained in all subjects at baseline evaluation and 24 hours after both allergen challenges. When placebo was inhaled before allergen challenge the sputum eosinophil percentage increased significantly (median 34%, $p < 0.05$ versus baseline). Compared with placebo, pretreatment with 50 μg salmeterol resulted in a significant inhibition of the increase in sputum eosinophil percentage at 24 hours after allergen (15%, $p < 0.05$ with respect to placebo; table 1).

Sputum ECP concentrations also increased at 24 hours after allergen inhalation in subjects pretreated with placebo (geometric mean 581 $\mu\text{g/ml}$, $p < 0.01$ versus baseline) as well as after pretreatment with salmeterol (410 $\mu\text{g/ml}$, $p < 0.01$ versus baseline) with no significant difference between placebo and salmeterol treatment (table 1).

Blood eosinophil percentages did not change with respect to the baseline value at 24 hours after allergen inhalation with either placebo or salmeterol. Compared with baseline values, serum ECP concentrations increased at 24 hours after allergen with placebo pretreatment (9.2 versus 6.0 $\mu\text{g/l}$, respectively, $p = 0.03$) and salmeterol pretreatment (9.4 versus 6.0 $\mu\text{g/l}$, respectively, $p = 0.02$; table 1).

Discussion

This study shows that salmeterol inhibits the increase in sputum eosinophils induced by allergen challenge in sensitised asthmatic subjects. Moreover, our data confirm that pretreatment with salmeterol prevents both EAR and LAR to allergen inhalation.

Eosinophil recruitment into the airway can be prevented by anti-inflammatory drugs such as inhaled corticosteroids.¹⁰ It is debatable whether long acting β_2 agonists also have some anti-inflammatory properties in vivo. In a group of subjects with mild asthma salmeterol significantly reduced serum ECP levels by approximately 50%.¹¹ Moreover, salmeterol significantly reduced the increase in plasma proteins in nasal lavage fluid of subjects with allergic rhinitis eight hours after nasal allergen challenge¹² and inhibited the recruitment of eosinophils in bronchial lavage fluid 24–48 hours after segmental allergen challenge.¹³ Pizzichini *et al* found that the late increase in sputum eosinophils after allergen inhalation was not prevented by pretreatment with salmeterol or with beclomethasone.⁴ The disagreement between our results and the results of Pizzichini *et al* may be explained by the different study design. In the study by Pizzichini *et al* each subject repeated five allergen challenges and four hypertonic saline sputum inductions for each allergen challenge. This could have resulted in a progressive increase in airway inflammation in each subject during the progression of the study, leading to a more persistent eosinophilic inflammation and consequently to the low repeatability reported by these authors in sputum eosinophil percentages measured before each allergen challenge. In fact, a small change in markers of airway inflammation can be induced by repeated hypertonic saline challenges¹⁴ and allergen inhalation increases non-specific bronchial reactivity for many days.¹⁵

Although airway eosinophilic recruitment induced by allergen challenge was inhibited by salmeterol, ECP levels in induced sputum obtained after pretreatment with salmeterol were no different from those obtained after placebo pretreatment. While it has been shown that salmeterol can inhibit diapedesis of inflammatory cells into the tissue at bronchodilator doses,¹⁶ higher concentrations of drug are required to affect ECP release from eosinophils.¹⁷ On the other hand, ECP levels were more variable than eosinophil percentages and there is therefore considerable potential for a type II error in failing to detect a modest effect of salmeterol on ECP levels.

Tolerance to some anti-inflammatory effects of salmeterol has been reported as a possible explanation for the loss of the protective effect of salmeterol on allergen challenge after

repeated administrations of the drug.¹⁸ This fact could produce a discrepancy between the acute and chronic effects of salmeterol on airway inflammation in asthma.

In conclusion, we have shown that a single dose of salmeterol reduces the recruitment of eosinophils in the airways after allergen challenge, in addition to the prevention of the early and late airway responses.

Source of study drugs: GlaxoWellcome, Verona, Italy.

- 1 Tilles SA, Nelson HS. Long-acting inhaled beta agonists. *J Asthma* 1995;32:397–404.
- 2 Twentyman OP, Finnerty JP, Harris A, *et al*. Protection against allergen-induced asthma by salmeterol. *Lancet* 1990;336:1338–42.
- 3 Dahl R, Pederson B. The influence of inhaled salmeterol on bronchial inflammation. A bronchoalveolar lavage study in patients with bronchial asthma. *Eur Respir Rev* 1991;1:277–85.
- 4 Pizzichini MMM, Kidney JC, Wong BJO, *et al*. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. *Eur Respir J* 1996;9:449–55.
- 5 Paggiaro PL, Dente FL, Morelli MC, *et al*. Post-allergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. *Am J Respir Crit Care Med* 1994;149:1447–51.
- 6 Pin I, Gibson PG, Kolendowicz R, *et al*. Use of induced sputum cell counts to investigate airway inflammation in asthma. *Thorax* 1992;47:25–9.
- 7 Bacci E, Cianchetti S, Paggiaro PL, *et al*. Comparison between hypertonic and isotonic saline-induced sputum in the evaluation of airway inflammation in subjects with moderate asthma. *Clin Exp Allergy* 1996;26:1395–400.
- 8 Ahlstedt S. Clinical application of eosinophil cationic protein in asthma. *Allergy Proc* 1995;16:59–62.
- 9 Glantz SA. *Primer of biostatistics*. New York: McGraw-Hill Inc, 1987.
- 10 Ådelroth E, Rosenhall L, Johansson S-Å, *et al*. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. *Am Rev Respir Dis* 1990;142:91–9.
- 11 Di Lorenzo G, Morici G, Norrito F, *et al*. Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. *Clin Exp Allergy* 1995;25:951–6.
- 12 Birchall MA, O'Connell F, Henderson J, *et al*. Topical salmeterol reduces protein content of nasal lavage fluid in response to allergen and histamine challenge: double-blind cross-over placebo-controlled studies in adults. *Am J Rhinology* 1996;10:251–6.
- 13 Brick JJ, Hinton KL, Vuchinich T, *et al*. Effects of salmeterol on eosinophil recruitment to the airway following segmental antigen challenge (SAC) in atopic asthmatics. *Am J Respir Crit Care Med* 1996;153(Part 2):A804.
- 14 Holz O, Richter K, Jörres RA, *et al*. Changes in sputum composition between two inductions performed on consecutive days. *Thorax* 1998;53:83–6.
- 15 Cartier A, Thompson NC, Frith PA, *et al*. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. *J Allergy Clin Immunol* 1982;70:170–7.
- 16 Whelan CJ, Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. *Br J Pharmacol* 1992;105:831–8.
- 17 Rabe KF, Giebysz MA, Dent G, *et al*. Salmeterol is a competitive antagonist at β -adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. *Eur J Pharmacol* 1993;231:305–8.
- 18 Giannini D, Carletti A, Dente FL, *et al*. Tolerance to the protective effect of salmeterol on allergen challenge. *Chest* 1996;110:1452–7.